Quick answer: Enclomiphene has a half-life of approximately 10 hours. This is its most important pharmacokinetic advantage over racemic Clomid, which contains zuclomiphene with a half-life of approximately 30 days. The short half-life of enclomiphene produces predictable, non-accumulating, consistent effects throughout a treatment course.
What Is the Half-Life of Enclomiphene?
The half-life of a compound is the time required for serum concentration to fall by 50 percent after absorption. For enclomiphene (trans-clomiphene), pharmacokinetic studies place the half-life at approximately 10 hours. This means that after a single oral dose, roughly half the absorbed compound is cleared by the 10-hour mark, and substantially all of it is cleared within 2 to 3 days. At daily dosing, steady state is reached within 2 to 3 days of starting, and full clearance after the last dose occurs within 2 to 3 days of stopping.
To understand why this matters, it is necessary to compare it to the other isomer in racemic clomiphene (Clomid): zuclomiphene.
Why the Half-Life Advantage Over Clomid Is Clinically Significant
Racemic clomiphene (Clomid) is a 50/50 mixture of two geometric isomers: enclomiphene (the trans isomer) and zuclomiphene (the cis isomer). Both bind to estrogen receptors, but they behave very differently in the body.
Enclomiphene is a pure estrogen receptor antagonist at the hypothalamus and pituitary. It blocks estrogen negative feedback and drives LH and FSH upward. Its 10-hour half-life means it exerts this effect and then clears promptly.
Zuclomiphene is also an estrogen receptor ligand, but with partial agonist activity. At the hypothalamus, it can exert weak estrogenic effects. Its half-life is approximately 30 days. This means that with daily Clomid use over weeks and months, zuclomiphene accumulates in serum to concentrations several times higher than enclomiphene, because it clears so slowly while new doses continue to add more.
The practical consequence is that long-term Clomid use is pharmacologically dominated by the accumulated zuclomiphene pool, not by the freshly absorbed enclomiphene. This zuclomiphene pool can partially counteract the intended anti-estrogenic hypothalamic effect, blunting the LH-raising benefit. It is also implicated in the mood-related side effects (irritability, depression, cognitive fog) reported by some men using Clomid long-term, since these effects are consistent with partial estrogenic activity in the brain.
With enclomiphene, there is no zuclomiphene. Every dose clears within 2 to 3 days. There is no progressive accumulation, no partial agonist noise at the hypothalamus, and no delayed estrogenic signal building up over weeks. The pharmacological signal is clean and consistent from day 1 through the last day of the research protocol.
Practical Implications for Research Protocols
The short half-life has several practical implications that are relevant when designing enclomiphene research protocols.
Predictable dose-response: Because enclomiphene reaches steady state within 2 to 3 days and maintains consistent trough and peak concentrations with daily dosing, the dose-response relationship is linear and predictable. Doubling the dose roughly doubles the receptor occupancy effect. This makes titration straightforward.
No accumulation over time: A 12-week protocol on enclomiphene exposes the subject to the same pharmacological signal in week 12 as in week 1. There is no late-cycle accumulation changing the effect profile. This is unlike Clomid, where the zuclomiphene burden increases progressively over weeks.
Rapid washout: If a research subject needs to pause or stop the protocol, full clearance occurs within 2 to 3 days of the last dose. This contrasts sharply with Clomid, where the accumulated zuclomiphene pool requires weeks to clear after stopping. A researcher stopping Clomid after 8 weeks of daily use would still carry pharmacologically active zuclomiphene concentrations for weeks afterward.
For cycling applications: Researchers investigating on-off cycling protocols (periods of use alternating with periods of non-use) can design clean washout periods with enclomiphene. A 3-day washout is sufficient for the compound to be effectively cleared. This is not practical with racemic Clomid due to the zuclomiphene accumulation problem.
Morning dosing convenience: A single morning dose achieves reliable coverage throughout the day. Given the 10-hour half-life, peak concentrations occur a few hours after dosing and trough concentrations at the 10-hour mark remain at half the peak value. Once-daily dosing is sufficient to maintain consistent hypothalamic receptor occupancy throughout the waking day.
Dosage Note
Elite Bio Supply’s enclomiphene is supplied as 50 mg tablets in 5-count packs. Research protocols typically use 12.5 to 25 mg per day. Tablets are split to achieve these doses. Given the 10-hour half-life, splitting the total daily dose into two smaller doses (morning and midday) is sometimes explored in research designs to maintain more even receptor occupancy throughout the day, but once-daily dosing has been the standard in published trials.
Frequently Asked Questions
Does a shorter half-life mean enclomiphene is less effective than Clomid?
No. A shorter half-life does not imply lower efficacy. What matters is the receptor occupancy achieved during the dosing interval and the consistency of the pharmacological signal. Daily enclomiphene at 25 mg maintains consistent estrogen receptor antagonism at the hypothalamus and pituitary throughout each 24-hour period. The Phase III trials using this dosing schedule achieved 77 percent testosterone normalization, which is equivalent to or better than outcomes reported with racemic Clomid in comparable secondary hypogonadism populations. The shorter half-life actually improves the pharmacological profile by eliminating the accumulating zuclomiphene problem.
How long does it take to reach steady state with daily dosing?
With a half-life of 10 hours, steady state is reached after approximately 4 to 5 half-lives, which is 40 to 50 hours. In practical terms, steady-state enclomiphene concentrations are established within 2 to 3 days of starting daily dosing. From day 3 onward, trough and peak concentrations are essentially stable from day to day. This is a faster steady-state achievement than drugs with longer half-lives, which can take weeks to plateau.
Will enclomiphene test positive on hormone panels taken at different times of day?
Enclomiphene itself is not measured on standard hormone panels. Panels measure testosterone, LH, FSH, estradiol, and related hormones, not the SERM compound. The time of day matters for testosterone measurement (morning levels are highest due to circadian variation), but the presence or absence of enclomiphene in circulation at the time of blood draw does not affect the hormone values directly in a way that requires special timing adjustment, provided the subject has been on daily dosing long enough to reach steady state.
Sourcing Enclomiphene in Canada
Elite Bio Supply provides pharmaceutical-grade enclomiphene citrate with verified purity by third-party testing. Domestic Canadian shipping, no customs exposure. Certificates of analysis available for each batch. The product you receive matches the chemical specification of enclomiphene used in published Phase II and Phase III trials.
Related Guides
- Enclomiphene Dosage Guide
- Clomid vs Enclomiphene: A Comparison
- Enclomiphene for Secondary Hypogonadism
- Buy Enclomiphene in Canada
References
- Wiehle RD et al. (2013). Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial. Fertil Steril. doi:10.1016/j.fertnstert.2013.02.040
- Wiehle RD et al. (2014). Enclomiphene citrate stimulates testosterone production while preventing oligospermia. Fertil Steril. PMID 25044085
- Earl JA, Kim ED (2019). Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. PMID 31063005
- Ramasamy R et al. (2014). Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. J Urol. PMID 24657837
Interested in enclomiphene’s clean pharmacokinetic profile? View our enclomiphene listing for current stock and COA documentation.
Elite Bio Supply sells research compounds for research purposes only. This content does not constitute medical advice. Consult a qualified physician before use.